Endocrine-Related Cancer

Article	Citations
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	110
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	66
Acknowledgement to reviewers	62
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	56
Metastatic neuroendocrine neoplasms of the breast: a systematic review	54
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance	40
Update on the genetics of paragangliomas	39
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	36
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study	34
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	34
NP-101 in Combination with Nivolumab and Ipilimumab in Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECs): A Pilot Study	31
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	31
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	31
Targeting growth hormone in cancer: future perspectives	29
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	29
Defining aging-associated factors that increase susceptibility to prostate cancer	27
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	27
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	26
Metabolically active brown adipose tissue in PPGL: an observational cohort study	24
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	23
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	23
PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	21
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	21
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	20
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	20

Determinants of False Positive Plasma Free Metanephrines and Methoxytyramine: The Role of Medications and Chronic Disease	20
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	19
Impact of sex hormones on development and progression in NEN: a new therapeutic target?	19
Peptide receptor radionuclide therapy in malignant insulinoma	18
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	17
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	17
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	16
Gender-affirming care and endocrine-related cancers	16
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	15
Whole-exome sequencing of rectal neuroendocrine tumors	15
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	15
Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC	15
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	14
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	14
Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma	13
Immunotherapy for endocrine tumours: a clinician’s perspective	13
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	13
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	13
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	13
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	13
From bench to bedside in the sella: translational developments in pituitary tumour genetics	12
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	12
Acknowledgement to reviewers	12
Steroid profile in patients with breast cancer and in mice treated with mifepristone	12
Exploring stem cell biology in pituitary tumors and derived organoids	12
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	12
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	12
Acknowledgement to reviewers	12
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	12
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60	12
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
Clinical features of plurihormonal pituitary adenoma subtypes	11
Systems biology successes and areas for opportunity in prostate cancer	11
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	11
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer	10
NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors	10
Relationship between vascular density and microenvironment in medullary thyroid carcinoma	10
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	10
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC	10
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	10
Genetic disorders and insulinoma/glucagonoma	10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	10
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	10
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2	10

Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	10
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	10
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	10
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	9
In memoriam: Charis Eng MD PhD (1962–2024)	9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	9
Beyond the three P’s: adrenal involvement in MEN1	9
Non-pituitary GH regulation of the tissue microenvironment	9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	9
Deiodinases in thyroid tumorigenesis	9
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	9
Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model	9
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	8
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	8
MicroRNAs as regulators of tumor metabolism	8
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	8
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A	8
Surrogate molecular classification of LAR breast cancer in routine workflow	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	7
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	7
Chemoembolization using streptozotocin versus embolization in metastatic NETs	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	7
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	7
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	7
Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis	7
Acknowledgement to reviewers	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
Characterization of small intestinal neuroendocrine tumorlets	7
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	7
Rethinking paraganglioma management: distinct clinical pathways for head and neck versus other sites	7
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	7
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
Cryoablation of bone metastases in thyroid and adrenocortical cancers	7
Insulinomatosis: new aspects	7
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	7
GLP1 receptor agonism alters growth and therapeutic response in prostate cancer	6
The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	6
Predictors of cancer in patients with endogenous Cushing’s syndrome	6
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	6
Inflammation-based score in pediatric adrenocortical carcinoma	6
Adrenal tumors in the elderly	6
Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs	6
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	6
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	5
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	5
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	5
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	5
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	5
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	5
Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines	5
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	5
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	5
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	5
Mobile Elements in Pituitary Neuroendocrine Tumors: Integrative Evidence and Future Directions	5
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	5
Hallmarks of disease: how tuned hierarchies of intelligent molecular neural networks (MNNs) may matter	5
Sig27 stratifies prostate cancer recurrence by assessing the immunosuppressive properties of tumors	5
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	5
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	5
Expanding horizons in Endocrine-Related Cancer: innovation, imagination, and a shared global vision	5
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	5
HMGCS1 as a Potential Mediator of Resistance to EZH2 Inhibition via Ferroptosis mediated by PI3K/AKT/mTOR Pathway in the Pancreatic Neuroendocrine Neoplasms	5
Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside	5
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	5

Comprehensive analysis of germline and somatic SDHA alterations reveals rare incidental germline variants and prognostic implications of somatic loss in breast cancer	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo	4
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	4
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	4
Mechanisms of resistance to RET-directed therapies	4
Second primary cancers and survival among neuroendocrine tumor patients	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	4
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	4
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	4
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	4
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	4
Improved and individualized approach to adrenal surgery	4
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	4
Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
Impact of presurgical beta-blockade on surgical outcomes in patients with PPGLs	3
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	3
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	3
Therapeutic inhibition of ATR in differentiated thyroid cancer	3
Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women	3
Proteomic Signatures of Adipocyte Recruitment in Breast Cancer	3
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
Breast cancer metastasis in obesity: extracellular vesicles as drivers	3
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	3
Predictive model for the diagnosis of Ectopic Cushing Syndrome	3
Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms	3
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	3
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Heme-oxygenase-1: a key player in thyroid carcinoma development	3
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	3
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	3
Autocrine/paracrine growth hormone in cancer progression	3
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	2
Impact of treatment on quality of life in neuroendocrine neoplasm survivors	2
BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation	2
Targeting RET in medullary thyroid cancer	2
Targeting METTL3 induces a metabolic vulnerability in ER+ breast carcinoma cells	2
Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study	2
GIPR in GH-PitNETs: molecular and functional insights	2
A study of acromegaly-associated headache with somatostatin analgesia	2
Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage	2
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	2
Talking about sex: erectile dysfunction in the oncology patient	2
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	2
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	2
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	2
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer	2
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma	2
Identification of protein-coding genes associated with metastatic prostate cancer	2
The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma	2
Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations	2
Giant cell tumor of the sphenoid bone: a systematic literature review with illustrative cases	2
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy	2
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	2
Mechanisms of RET-mediated signal transduction	2
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	2
A novel 2D and 3D model for primary adrenocortical carcinoma of advanced and metastasized stage co-secreting cortisol, aldosterone, testosterone, 18-oxocortisol and 18-hydroxycortisol	2
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	2
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	2
Genomic testing for RET in the clinic: UK and global perspective	2
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	2
Body composition in recurrent prostate cancer and the role of steroidogenic genotype	2
Changes in categorization or nomenclature within neuroendocrine tumors	2
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer	2
Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas	2
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	2
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	2
Disease relapse in relation to lymph node sampling in lung carcinoid patients	2
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	2
Dysregulation of splicing variants and spliceosome components in breast cancer	2
Aggressive versus indolent insulinomas: new clinicopathological insights	2
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	2
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	2
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	2